Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107555 - 107555
Published: Dec. 1, 2024
Language: Английский
Current Cardiology Reports, Journal Year: 2025, Volume and Issue: 27(1)
Published: Jan. 7, 2025
Language: Английский
Citations
1
The American Journal of Emergency Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
0
ESC Heart Failure, Journal Year: 2025, Volume and Issue: unknown
Published: April 17, 2025
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones heart failure treatment. Nevertheless, while cardiovascular beneficial effects these drugs have been clearly demonstrated by several clinical trials, in practice, it remains challenging to identify appropriate timing start SGLT2 inhibitors. The potential risk side effects, like genito‐urinary infections and interaction with other drugs, may often lead delay prescription acute setting. However, studies safety prognostic impact hospitalized patient, suggesting that treatment initiation during hospitalization or early post‐discharge an ideal therapeutic option. In this review, we discuss trials on administration supporting introduction optimize efficacy patients myocardial infarction are also discussed. Based review existing evidences, a practical flowchart setting is proposed.
Language: Английский
Citations
0
Cardiovascular Diabetology, Journal Year: 2025, Volume and Issue: 24(1)
Published: April 18, 2025
The pericoronary fat attenuation index (FAI) is a novel biomarker that serves as an indicator of coronary artery inflammation. Dapagliflozin has become important component standard treatment for type 2 diabetes because its cardioprotective and renoprotective effects. objective this research was to explore how dapagliflozin impacts inflammation in T2DM patients establish theoretical framework the protective role cardiovascular system. This retrospectively included 271 treated with computed tomography angiography (CCTA) at Hebei Provincial People's Hospital from January 2021 November 2024, 103 receiving therapy (dapagliflozin+) 168 not (dapagliflozin-) (oral 10 mg/day no less than 6 months). Baseline clinical information, laboratory markers, CCTA-related metrics were collected analysed across both groups. relationship between FAI using multiple linear regression control confounding variables, correlation two variables further examined various subgroups. Compared those dapagliflozin- group, dapagliflozin+ group younger (P<0.001), proportion men higher (P<0.05). There between-group differences baseline data, such course, BMI, blood lipid status (P>0.05). LAD RCA lower other groups, average three arteries also significantly lower, while there significant difference LCX (LAD: group: -85.50 (-90.43, -78.27)，dapagliflozin+ group：-86.94 (-92.81, -81.57)，P= 0.044；RCA：dapagliflozin- group：-86.31 (-92.12, -80.09), group：-88.79 (-94.59, -83.31), P= 0.019; Mean: -84.05 (-87.73, -77.45), -84.88 (-89.82, -79.67), 0.022; LCX: group：-77.81 (-82.57, -71.75), -78.25 (-84.56, -72.15), P = 0.260). Multiple analyses revealed independent association decreased β=-2.449; RCA: β=-3.897; values are all 0.05). different subsets patients. associated reduction patients, which may partly explain beneficial effects on reducing risk.
Language: Английский
Citations
0
Nature Reviews Cardiology, Journal Year: 2025, Volume and Issue: unknown
Published: April 28, 2025
Language: Английский
Citations
0
JACC Heart Failure, Journal Year: 2025, Volume and Issue: 13(5), P. 829 - 839
Published: May 1, 2025
Language: Английский
Citations
0
Heart Failure Reviews, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 15, 2024
Language: Английский
Citations
0
Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107555 - 107555
Published: Dec. 1, 2024
Language: Английский
Citations
0